US equities |
GOOGL $281.38 ▼-13.39% GOOG $279.35 ▼-13.22% MSFT $529.17 ▼-0.35% META $626.07 ▲+2.22% MU $932.03 ▼-5.21% NVDA $212.79 ▼-1.20% AMZN $244.76 ▼-3.86% AAPL $349.94 ▲+1.78%
FinancialContent

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

13.65 +0.09 (+0.66%)
Delayed Quote Updated: 2:19 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Revenue Jumps 43% in Q2 ↗
Via The Motley Fool
News headline image
MediWound (MDWD) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MediWound Ltd (NASDAQ:MDWD) Reports Mixed Q2 2025 Results with Revenue Growth but Wider-Than-Expected Losses ↗
MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress. 
Via Chartmill
News headline image
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
MediWound (MDWD) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 21, 2025 ↗
 
Via Benzinga
News headline image
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 19, 2025 ↗
 
Via Benzinga
News headline image
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >